Lisa M Stuart
Overview
Explore the profile of Lisa M Stuart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim M, Singh M, Lee B, Hibbs M, Richardson K, Ellies L, et al.
Oncogenesis
. 2022 Oct;
11(1):60.
PMID: 36207293
The MYC proto-oncogene (MYC) is one of the most frequently overexpressed genes in breast cancer that drives cancer stem cell-like traits, resulting in aggressive disease progression and poor prognosis. In...
2.
Beveridge D, Richardson K, Epis M, Brown R, Stuart L, Woo A, et al.
Sci Rep
. 2021 Sep;
11(1):18003.
PMID: 34504167
RNA-based therapeutics are emerging as innovative options for cancer treatment, with microRNAs being attractive targets for therapy development. We previously implicated microRNA-642a-5p (miR-642a-5p) as a tumor suppressor in prostate cancer...
3.
Brown R, Richardson K, Kalinowski F, Epis M, Horsham J, Kabir T, et al.
Methods Mol Biol
. 2017 Nov;
1699:155-178.
PMID: 29086376
MicroRNAs (miRNAs) are a family of short noncoding RNA molecules that fine-tune expression of mRNAs. Often their altered expression is associated with a number of diseases, including cancer. Given that...
4.
Epis M, Giles K, Beveridge D, Richardson K, Candy P, Stuart L, et al.
Oncotarget
. 2017 Sep;
8(33):55116-55134.
PMID: 28903407
RNA-based therapeutics could represent a new avenue of cancer treatment. miRNA 331-3p (miR-331-3p) is implicated in prostate cancer (PCa) as a putative tumor suppressor, but its functional activity and synergy...
5.
Kabir T, Ganda C, Brown R, Beveridge D, Richardson K, Chaturvedi V, et al.
Hepatology
. 2017 Aug;
67(1):216-231.
PMID: 28833396
Conclusion: We identified a mechanism for acquiring SR in HCC that is through the aberrant expression of the TYRO3/phosphoinositide 3-kinase/protein kinase B signal transduction pathway, and that can be overcome...
6.
Giles K, Brown R, Ganda C, Podgorny M, Candy P, Wintle L, et al.
Oncotarget
. 2016 May;
7(22):31663-80.
PMID: 27203220
microRNA-7-5p (miR-7-5p) is a tumor suppressor in multiple cancer types and inhibits growth and invasion by suppressing expression and activity of the epidermal growth factor receptor (EGFR) signaling pathway. While...
7.
Giles K, Kalinowski F, Candy P, Epis M, Zhang P, Redfern A, et al.
Mol Cancer Ther
. 2013 Sep;
12(11):2541-58.
PMID: 24026012
Elevated expression and activity of the epidermal growth factor receptor (EGFR) is associated with development and progression of head and neck cancer (HNC) and a poor prognosis. Clinical trials with...
8.
Redfern A, Colley S, Beveridge D, Ikeda N, Epis M, Li X, et al.
Proc Natl Acad Sci U S A
. 2013 Apr;
110(16):6536-41.
PMID: 23550157
The cytoplasmic RNA-induced silencing complex (RISC) contains dsRNA binding proteins, including protein kinase RNA activator (PACT), transactivation response RNA binding protein (TRBP), and Dicer, that process pre-microRNAs into mature microRNAs...
9.
Hatchell E, Colley S, Beveridge D, Epis M, Stuart L, Giles K, et al.
Mol Cell
. 2006 Jun;
22(5):657-68.
PMID: 16762838
Steroid receptor RNA activator (SRA), the only known RNA coactivator, augments transactivation by nuclear receptors (NRs). We identified SLIRP (SRA stem-loop interacting RNA binding protein) binding to a functional substructure...